Cellectar Biosciences, Inc.

Financial Services · Biotechnology
Listed: NASDAQ: CLRB

Facts

as of Nov 17, 2026

Cellectar Biosciences is focused on the discovery and development of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations.

Legal name
Cellectar Biosciences, Inc.
Headquarters
Florham Park, United States
Employees
201-500estimated range
Listing
NASDAQ: CLRB
Register numbers
NAME cellectar biosciences inc
Official records
SEC CIK 1279704
Website
cellectar.com

These are the key facts about Cellectar Biosciences, Inc. on Alion as of Nov 17, 2026. Cellectar Biosciences, Inc. is headquartered in Florham Park, United States. It has raised $50M in 3 funding rounds. The latest round is Venture - Series Unknown of $24.5M, announced in 2023.

Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

What the registers and the postings say about this employer.

Legal entity active
Cellectar Biosciences, Inc.
Not checked
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices

Footprint

Hiring in 1 city in 1 country.

1Cities
1Countries
SiteTypeOpen rolesHires most forEngineering
Florham Park United StatesHeadquarters0
Source: office addresses in postings and company registers

Financials

Funding rounds, investors and revenue on record.

$50MTotal raised
$4MPublic grants2 public grants
Venture - Series UnknownLatest round
5Rounds and grants
Money by yearUSD, rounds and grants
2023$24.5M1 record
2022$2M1 record
2021$2M1 record
2020$20.5M1 record
2019$5M1 record
Largest rounds and grants
Sources: funding announcements, grant and company registers

Milestones

Nov 2026
Went public NASDAQ: CLRB
Sep 22, 2023
Sep 8, 2023
Sep 16, 2022
Won a grant $2M · CORDIS
Jan 8, 2021
Each milestone is dated by its source: registers, filings, the press